Integra reaffirms 2026 adjusted EPS of $2.40 to $2.50 while guiding Q3 revenue to $410M-$425M (NASDAQ:IART)
· seekingalpha.com
Integra LifeSciences (IART) Q2 2026 earnings call recap: revenue/EPS, reaffirmed 2026 guidance, SurgiMend relaunch timing, FX, leverage, risks—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...